Overview

Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology

Status:
Recruiting

Trial end date:
2022-04-03

Target enrollment:

Participant gender:

Summary

Determination of a safe dose for nintedanib+nivolumab combination therapy and the generation of exploratory efficacy data in pretreated patients with advanced or metastatic NSCLC of adenocarcinoma histology.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

AIO-Studien-gGmbH

Treatments:

Nintedanib
Nivolumab